Trial Profile

Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Perception

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tasimelteon (Primary)
Indications Circadian rhythm sleep disorders
Focus Adverse reactions; Registrational
Sponsors Vanda Pharmaceuticals

Most Recent Events

01 Apr 2024 Planned End Date changed from 1 Dec 2018 to 5 Dec 2024.
01 Apr 2024 Planned primary completion date changed from 1 Dec 2018 to 5 Dec 2024.
01 Apr 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com